# Immunoassay Analyzers Market

> 免疫测定分析仪市场研究报告信息按仪器（免疫荧光、化学发光、ELISA、放射免疫测定）、按应用（传染病、自身免疫性疾病、艾滋病）、最终用户（医院）和地区（北美、欧洲、亚太地区和世界其他地区）-2032 年之前的市场预测

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.4%
- **2024:** $ 1.22 Billion
- **2025:** $ 1.29 Billion
- **2035:** $ 2.18 Billion
- **Key Players:** Companies such as Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Ortho Clinical Diagnostics (US), Beckman Coulter (US), Bio-Rad Laboratories (US), PerkinElmer (US), Molecular Devices (US) are some of the major participants in the market.

**Report ID:** MRFR/MED/0694-HCR · **Pages:** 80 · **Author:** Satyendra Maurya & Kinjoll Dey · **Last Updated:** September 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/immunoassay-analyzers-market-1200

---

## Market Summary

## **Global Immunoassay Analyzers Market Overview**

The Immunoassay Analyzers Market Size was valued at USD 1.1 billion in 2022. The Immunoassay Analyzers market is projected to grow from USD1.1594 Billion in 2023 to USD 1.765867 billion by 2032, exhibitinga compound annual growth rate (CAGR) of 5.40% during the forecast period (2023 - 2032). Increased prevalence of infectious immunological or metabolic diseases, rising demand for advanced diagnostic devices, and recent trends of automation and integration are the key market drivers enhancing market growth.

Source Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review

## **Immunoassay Analyzers Market Trends**

The burden of chronic diseases, the massive infection rate, and the COVID-19 pandemic have necessitated using immune-diagnostic assays for containment and management. Immunoassay tests are an essential diagnostic tool that offers reliable and low-cost detection of pathogens or target molecules. These tests are used to diagnose both highly prevalent and chronic diseases. On a  scale, immunoassays have become the frontline diagnostics for detecting several pathogens and pathophysiological conditions.

The increasing demand for the early-stage diagnosis of disease conditions using immunoassay products is another major factor driving the market growth. ly, the number of diabetics is expected to grow from 643 million in 2030 to 783 million by 2045. Diabetes resulted in 6.7 million deaths worldwide in 2021, while 541 million people are estimated to be at risk of developing diabetes. This factor drives the market CAGR.

The WHO underlined the concern of HIV, which has claimed over 33 million lives; an estimated 38 million people have HIV infections. Similarly, The International Agency for Research on Cancer and GLOBOCAN estimated 19.3 million new cases of cancer and 10.0 million deaths in 2020. Breast cancer dominates this estimate with 2.3 million new cases, followed by lung, colorectal, prostate, and stomach cancer.

Additionally, the major factors contributing to the growth of the clinical immunoassay analyzer market include the increasing prevalence of chronic & infectious diseases, adoption of advanced immunoassay tests, increasing aging population, development in R&D activities to enhance the product, and high demand for next-generation immunodiagnostics. However, high costs and limited reimbursements restrain market growth. The introduction of paper-based electrochemical immunoassay devices and increasing healthcare infrastructure provide lucrative Immunoassay Analyzers market revenue during the forecast period.

## **Immunoassay Analyzers Market Segment Insights**

### **Immunoassay Analyzers Instruments Insights**

Based on instruments, the Immunoassay Analyzers market segmentation includes immunofluorescence, chemiluminescence, ELISA, and radioimmunoassay application. The ELISA segment dominated the market due to rapid tests, ELISpot, western blotting, radioimmunoassay, and other technologies. The large share of this technology segment can primarily be attributed to the increasing use of ELISA tests in cancer diagnosis, infectious diseases detection, and therapeutic drug level monitoring.

### **Immunoassay Analyzers Application Insights**

Based on Application, the Immunoassay Analyzers market segmentation includes infectious diseases, autoimmune diseases, and AIDS. The infectious diseases segment dominated the market due to the rising prevalence of infectious diseases and the increase in product launches catering to infectious disease diagnosis to drive the segment's growth.

**Figure 1 Immunoassay Analyzers Market, by Application, 2022&2032 (USD billion)**

**_Source Secondary Research, Primary Research, MRFR Database, and Analyst Review_**

### **Immunoassay Analyzers End-User Insights**

The Immunoassay Analyzers market segmentation, based on end-user, includes hospitals. The hospital segment dominated the market because the large share can be attributed to the high demand for immunoassay products in hospitals with increased hospitalizations due to chronic and infectious diseases. The increasing number of corporate hospital chains further boosts market demand for automated immunoassay analyzers.

### **Immunoassay Analyzers Regional Insights**

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American immunoassay analyzers market will dominate this market due to the commercial availability of products with advanced technologies. These products' high adoption rate will boost the Region's market growth.

Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2 IMMUNOASSAY ANALYZERS MARKET SHARE BY REGION 2022 (%)**

**_Source Secondary Research, Primary Research, MRFR Database, and Analyst Review_**

Europe Immunoassay Analyzers market accounts for the second-largest market share due to sophisticated healthcare infrastructure, high disposable income, increasing healthcare expenditure, and growing awareness about the early diagnosis of diseases. Further, the German Immunoassay Analyzers market held the largest market share, and the UK Immunoassay Analyzers market was the fastest-growing market in the European Region.

The Asia-Pacific Immunoassay Analyzers Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due tothe rapidly growing number of manufacturing facilities in the Region is boosting the growth in this Region. Moreover, China’s Immunoassay Analyzers market held the largest market share, and the Indian Immunoassay Analyzers market was the fastest-growing market in the Asia-Pacific region.

**Immunoassay Analyzers Key Market Players& Competitive Insights**

Leading market players are investing heavily in research and development to expand their product lines, which will help the Immunoassay Analyzers market grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. The immunoassay analyzers industry must offer cost-effective items to expand and survive in a more competitive and rising market climate.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the Immunoassay Analyzers industry to benefit clients and increase the market sector. In recent years, the Immunoassay Analyzers industry has offered some of the most significant advantages to medicine. Major players in the Immunoassay Analyzers market, including F.

Hoffmann-La Roche Ltd. (Switzerland), Siemens Ltd. (Germany), Abbott (US), Beckman Coulter, Inc. (US), Ortho Clinical Diagnostics (US), bioMérieux Private Limited (France), Biokit S.A (Spain), The Binding Site Group Ltd. (UK), Immunodiagnostic Systems (UK), Merck KGaA (US), Olympus Corporation (Japan), Nova Century Scientific, Inc. (US), Thermo Fisher Scientific (US), DiaSorin S.p.A. (Italy) and Randox Laboratories Ltd. (UK)., and others, are attempting to increase market demand by investing in research and development operations.

- Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel.Roche received Emergency Use Authorization from the FDA for the Cobas SARS-CoV- 2 Duo for use on the fully automated Cobas 6800/8800 Systems.

Beckman Coulter Inc. is a Danaher Corporation company that develops, manufactures, and markets products that simplify, automate, and innovate complex biomedical testing. It operates in two industries Diagnostics and Life Sciences.Beckman Coulter agreed with Quidel Corporation to gain rights for the BNP assay's manufacturing, distribution, and sales by Quidel for Beckman Coulter analyzers.

**Key Companies in the immunoassay analyzers market include**

### Immunoassay Analyzers Market Industry Developments

- **Q2 2024: Siemens Healthineers launches Atellica CI Analyzer, expanding immunoassay testing capabilities for small- and mid-sized labs** Siemens Healthineers announced the commercial launch of the Atellica CI Analyzer, a new immunoassay and clinical chemistry analyzer designed to provide high-throughput testing for small- and mid-sized laboratories.
- **Q2 2024: Bio-Rad Laboratories Announces FDA Clearance of IH-500 Immunohematology Analyzer** Bio-Rad Laboratories received FDA 510(k) clearance for its IH-500 immunohematology analyzer, enabling automated blood typing and screening in U.S. clinical laboratories.
- **Q2 2024: QuidelOrtho Receives CE Mark for Savanna Multiplex Molecular Analyzer** QuidelOrtho announced it has received CE Mark for its Savanna multiplex molecular analyzer, expanding its portfolio of immunoassay and molecular diagnostic solutions in Europe.
- **Q3 2024: Abbott Launches Alinity m Resp-4-Plex Assay on Alinity m System in Europe** Abbott announced the European launch of its Alinity m Resp-4-Plex assay, which runs on the Alinity m system and enables simultaneous detection of multiple respiratory viruses using immunoassay technology.
- **Q3 2024: Roche launches new Elecsys Anti-Müllerian Hormone Plus immunoassay for fertility testing** Roche introduced the Elecsys AMH Plus immunoassay, a new diagnostic test for assessing ovarian reserve, expanding its immunoassay analyzer test menu.
- **Q3 2024: Beckman Coulter Diagnostics Receives FDA Clearance for DxI 9000 Access Immunoassay Analyzer** Beckman Coulter Diagnostics announced FDA clearance for its DxI 9000 Access Immunoassay Analyzer, a high-throughput system designed to improve laboratory workflow and efficiency.
- **Q4 2024: Siemens Healthineers to acquire immunoassay technology startup for $250 million** Siemens Healthineers announced an agreement to acquire a privately held immunoassay technology startup, aiming to strengthen its diagnostics portfolio and accelerate innovation in automated immunoassay analyzers.
- **Q4 2024: Mindray Launches CL-900i Plus Chemiluminescence Immunoassay Analyzer Globally** Mindray announced the global launch of its CL-900i Plus chemiluminescence immunoassay analyzer, designed for high-throughput and fully automated laboratory testing.
- **Q1 2025: Sysmex Launches HISCL-800 Immunoassay Analyzer in Japan** Sysmex Corporation launched the HISCL-800, a compact immunoassay analyzer for clinical laboratories, expanding its product offerings in the Japanese diagnostics market.
- **Q1 2025: Abbott Receives FDA Clearance for New Immunoassay Test on Alinity i Analyzer** Abbott announced FDA clearance for a new immunoassay test on its Alinity i analyzer, further expanding its menu of diagnostic tests for U.S. laboratories.
- **Q2 2025: BioMérieux Announces Partnership with Diagnostic Robotics to Integrate AI with Immunoassay Analyzers** BioMérieux entered a partnership with Diagnostic Robotics to integrate artificial intelligence into its immunoassay analyzer platforms, aiming to enhance diagnostic accuracy and workflow automation.
- **Q2 2025: Roche Receives CE Mark for New High-Sensitivity Troponin Immunoassay** Roche received CE Mark approval for its new high-sensitivity troponin immunoassay, designed for use on its cobas e analyzers to aid in the early diagnosis of myocardial infarction.

## **Immunoassay Analyzers Market Segmentation**

### **Immunoassay analyzers Instruments Outlook**

### **Immunoassay analyzers Application Outlook**

### **Immunoassay analyzers End-User Outlook**

### **Immunoassay Analyzers Regional Outlook**

## Market Drivers

### Focus on Personalized Medicine

免疫分析仪市场越来越关注个性化医疗，强调根据个体患者情况量身定制治疗策略。这种范式转变正在推动对先进免疫分析技术的需求，这些技术可以准确测量与各种疾病相关的特定生物标志物。随着医疗保健提供者寻求实施需要复杂诊断工具的精准医疗方法，该市场预计将增长。
基因检测和生物标志物发现的兴起进一步推动了这一趋势，因为这些因素是制定个性化治疗计划不可或缺的一部分。据估计，到 2030 年，个性化医疗市场的估值将超过 2 万亿美元，这表明免疫分析仪市场有巨大的机会进行创新和扩展该领域的产品。这种与个性化医疗的结合可以重新定义患者护理并提高治疗效果。

- PubMed 研究强调了生物标志物驱动的诊断和精准医疗应用的快速增长。研究表明，伴随诊断和生物标志物测试可显着改善治疗选择和临床结果，从而对能够支持个性化医疗保健策略的先进免疫分析仪产生强烈需求。

### Shift Towards Point-of-Care Testing

免疫分析仪市场正在见证向现场护理 (POC) 测试的显着转变，这正在改变诊断程序的格局。 POC 测试的优点是可以在患者护理现场快速提供结果，从而促进及时的临床决策。这种趋势在紧急情况和偏远地区尤为重要，因为这些地区传统实验室设施的使用可能受到限制。
POC 免疫分析仪市场预计将显着扩大，预计每年增长率约为 8%。这种增长是由于对分散式医疗解决方案的需求不断增长以及需要定期监测的慢性病患病率上升而推动的。随着医疗保健系统继续优先考虑以患者为中心的方法，免疫分析仪市场可能会通过纳入更多的 POC 测试解决方案来适应。

- IHME 数据表明，慢性病负担日益沉重，需要频繁监测和快速诊断。扩大医疗服务范围和分散式护理模式增加了对即时诊断解决方案的需求，支持更广泛地采用免疫分析仪，以更快地提供更接近患者的结果。

### Rising Incidence of Chronic Diseases

免疫分析仪市场受到慢性病发病率上升的显着影响，因此需要定期监测和及时诊断。糖尿病、心血管疾病和自身免疫性疾病等疾病变得越来越普遍，导致对可靠诊断工具的需求不断增加。根据最近的统计数据，慢性病约占全球死亡人数的 70%，这凸显了有效管理策略的迫切需要。
免疫分析仪市场预计将随着这一需求而增长，预计未来几年复合年增长率约为 6%。随着医疗保健系统努力改善患者的治疗结果，免疫分析仪市场可能在促进这些疾病的早期检测和持续管理方面发挥至关重要的作用，从而为整体公共卫生做出贡献。

- 世界银行健康指标显示，非传染性疾病占全球死亡率的大部分，医疗保健系统越来越多地投资于早期诊断和疾病监测。这一趋势增强了对用于管理糖尿病、心血管疾病和其他慢性病的免疫分析仪的需求。

### Increasing Investment in Healthcare Infrastructure

免疫分析仪市场受益于医疗保健基础设施投资的增加，这对于增强诊断能力至关重要。政府和私营实体正在分配大量资源来升级实验室设施并扩大先进诊断技术的使用范围。这种趋势在新兴经济体尤其明显，这些经济体正在齐心协力改善医疗保健服务系统。
预计该市场将经历强劲增长，随着新设施的建立和现有设施的现代化改造，预计每年增长约 5%。增强的医疗基础设施不仅促进了免疫分析仪的采用，而且还促进了旨在创新新诊断解决方案的研发活动。随着投资继续流入医疗保健领域，免疫分析仪市场有望蓬勃发展，最终有利于患者护理和治疗结果。

- 世界银行数据显示发达经济体和新兴经济体的医疗保健支出持续增长。对实验室现代化、诊断能力扩张和医疗保健基础设施发展的投资不断增加，为增加先进免疫分析仪的部署创造了有利条件。

### Technological Advancements in Immunoassay Analyzers

免疫分析仪市场正在经历技术进步的激增，这提高了诊断测试的效率和准确性。微流体、芯片实验室技术和自动化等创新正在简化流程，从而缩短测试结果的周转时间。例如，分析仪中人工智能的集成可以更精确地解释结果，这对于患者管理至关重要。
在这些进步的推动下，未来几年市场预计将以约 7% 的复合年增长率 (CAGR) 增长。此外，多重检测的发展允许同时检测多种生物标志物，这对于复杂的疾病管理特别有益。这一趋势表明免疫分析仪市场前景光明，因为它适应了医疗保健提供者不断变化的需求。

- PubMed 研究强调，自动化、多重测试、微流体和人工智能辅助诊断正在提高实验室效率和测试准确性。这些技术进步正在加速下一代免疫分析仪的采用，该分析仪能够处理更大的样本量并具有增强的分析性能。

## Future Outlook

The Immunoassay Analyzers Industry size is projected to reach USD 2.179 Billion by 2035, growing at a CAGR of 5.4%, driven by technological advancements, increasing demand for diagnostics, and rising healthcare expenditures.

**New opportunities:**

- Expansion into emerging markets with tailored product offerings. Development of portable immunoassay analyzers for point-of-care testing. Integration of AI for enhanced data analysis and predictive diagnostics.

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs.

## Segment Insights

### 按仪器：化学发光（最大）与免疫荧光（增长最快）

免疫分析仪市场展示了各种各样的仪器，主要以化学发光仪为主，占据最大的市场份额，占 48%。该方法因其高灵敏度和快速结果而在实验室中得到广泛采用，从而使其成为医疗保健提供者的首选。相比之下，免疫荧光正在成为一个重要的参与者，随着其在各种诊断和研究领域的应用扩展，占据了越来越大的市场份额。

雅培实验室通过自动化诊断系统继续推进基于化学发光的免疫分析平台。凭借卓越的灵敏度、快速的处理能力以及全球临床实验室的广泛采用，化学发光技术在 2024 年约占免疫分析仪市场的 48%。

### 按应用：传染病（最大）与自身免疫性疾病（增长最快）

免疫分析仪市场主要由其应用领域决定，主要是传染病领域，由于持续的全球健康挑战，免疫分析仪市场份额高达 42%。该部分包括对一系列传染源的测试，并且仍然是医疗保健提供者关注的关键领域，有助于及时诊断和治疗。在精准医学的进步以及医生和患者对自身免疫性疾病的早期诊断和管理的认识不断提高的推动下，自身免疫性疾病的新兴应用正在迅速被采用。

罗氏诊断通过不断的产品组合扩展和检测开发，在传染病诊断领域保持着强大的地位。 2024 年，传染病约占 42% 的市场份额，反映出全球对准确病原体检测和疾病监测解决方案的持续需求。

### 按最终用户：医院（最大）与实验室（增长最快）

在免疫分析仪市场，医院在最终用户领域占据最大份额，占 58%，反映了医院在诊断测试和患者护理方面的主导作用。这种广泛的利用源于医院环境中的大量诊断应用，以满足不同的医疗条件。实验室虽然目前所占份额较小，但在自动化和远程测试能力进步的推动下，正在成为市场的重要组成部分，从而提高了其运营效率和准确性。

西门子 Healthineers 通过集成诊断平台和工作流程自动化不断增强医院实验室能力。受高检测量、广泛的临床应用以及先进诊断基础设施投资不断增长的推动，到 2024 年，医院收入约占市场总收入的 58%。

## Regional Market Share Analysis

按地区划分，该研究提供了北美、欧洲、亚太地区和世界其他地区的市场洞察。由于具有先进技术的产品的商业可用性，北美免疫分析仪市场将主导该市场。这些产品的高采用率将推动该地区的市场增长。

- CDC 数据表明，大约十分之六的美国成年人患有至少一种慢性病，而十分之四的成年人患有两种或两种以上慢性病。巨大的诊断负担继续支持北美医疗机构对先进免疫分析仪的强劲需求。

此外，市场报告研究的主要国家包括美国、加拿大、德国、法国、英国、意大利、西班牙、中国、日本、印度、澳大利亚、韩国和巴西。

- GE Healthcare 继续投资先进的诊断和实验室技术，支持精准医疗和早期疾病检测。医疗保健诊断领域的持续创新有助于扩大实验室检测能力，巩固北美在先进免疫分析仪采用方面的领导地位。

由于先进的医疗基础设施、高可支配收入、不断增加的医疗支出以及对疾病早期诊断的认识不断增强，欧洲免疫分析仪市场占据第二大市场份额。此外，德国免疫分析仪市场占有最大的市场份额，英国免疫分析仪市场是欧洲地区增长最快的市场。

- 欧洲药品管理局 (EMA) 继续通过促进先进诊断技术获取的监管框架支持创新。对早期疾病检测、个性化医疗和实验室质量标准的高度重视鼓励整个欧洲医疗保健系统更广泛地使用免疫分析仪。

预计从 2023 年到 2032 年，亚太地区免疫分析仪市场将以最快的复合年增长率增长。这是由于该地区制造设施数量的快速增长正在推动该地区的增长。此外，中国的免疫分析仪市场占有最大的市场份额，印度免疫分析仪市场是亚太地区增长最快的市场。

## Competitive Benchmarking

领先的市场参与者正在大力投资研发以扩大其产品线，这将有助于免疫分析仪市场进一步增长。市场参与者还开展各种战略活动来扩大其足迹，重要的市场发展包括新产品发布、合同协议、并购、更高的投资以及与其他组织的合作。免疫分析仪行业必须提供具有成本效益的产品，以便在竞争更加激烈和不断发展的市场环境中扩张和生存。
 
本地制造以最大限度地降低运营成本是制造商在免疫分析仪行业中使用的关键业务策略之一，以使客户受益并扩大市场份额。近年来，免疫分析仪行业为医学提供了一些最显着的优势。免疫分析仪市场的主要参与者包括F. Hoffmann-La Roche Ltd.（瑞士）、Siemens Ltd.（德国）、Abbott（美国）、Beckman Coulter, Inc.（美国）、Ortho Clinical Diagnostics（美国）、bioMérieux Private Limited（法国）、Biokit S.A（西班牙）、The Binding Site Group Ltd.（英国）、Immunodiagnostic Systems（英国）、Merck KGaA （美国）、奥林巴斯公司（日本）、Nova Century Scientific, Inc.（美国）、Thermo Fisher Scientific（美国）、DiaSorin S.p.A.（意大利）和 Randox Laboratories Ltd.（英国）等公司正在尝试通过投资研发业务来增加市场需求。
 
Hoffmann-La Roche AG（俗称罗氏）是一家瑞士跨国医疗保健公司，在全球范围内通过制药和诊断两个部门开展业务。其控股公司罗氏控股股份公司 (Roche Holding AG) 的股票在瑞士第六交易所上市。公司总部位于巴塞尔。罗氏 Cobas SARS-CoV-2 Duo 已获得 FDA 的紧急使用授权，可用于全自动 Cobas 6800/8800 系统。 Beckman Coulter Inc. 是 Danaher Corporation 旗下公司，致力于开发、制造和销售可简化、自动化和创新复杂生物医学测试的产品。它在诊断和生命科学两个行业开展业务。Beckman Coulter 与 Quidel Corporation 达成协议，获得 Quidel 为 Beckman Coulter 分析仪制造、分销和销售 BNP 检测的权利。

## Recent News & Developments

- **Q2 2024: Siemens Healthineers launches Atellica CI Analyzer, expanding immunoassay testing capabilities for small- and mid-sized labs** Siemens Healthineers announced the commercial launch of the Atellica CI Analyzer, a new immunoassay and clinical chemistry analyzer designed to provide high-throughput testing for small- and mid-sized laboratories.
- **Q2 2024: Bio-Rad Laboratories Announces FDA Clearance of IH-500 Immunohematology Analyzer** Bio-Rad Laboratories received FDA 510(k) clearance for its IH-500 [immunohematology](https://www.marketresearchfuture.com/reports/immunohematology-market-42784) analyzer, enabling automated blood typing and screening in U.S. clinical laboratories.
- **Q2 2024: QuidelOrtho Receives CE Mark for Savanna Multiplex Molecular Analyzer** QuidelOrtho announced it has received CE Mark for its Savanna multiplex molecular analyzer, expanding its portfolio of immunoassay and molecular diagnostic solutions in Europe.
- **Q3 2024: Abbott Launches Alinity m Resp-4-Plex Assay on Alinity m System in Europe** Abbott announced the European launch of its Alinity m Resp-4-Plex assay, which runs on the Alinity m system and enables simultaneous detection of multiple respiratory viruses using immunoassay technology.
- **Q3 2024: Roche launches new Elecsys Anti-Müllerian Hormone Plus immunoassay for fertility testing** Roche introduced the Elecsys AMH Plus immunoassay, a new diagnostic test for assessing ovarian reserve, expanding its immunoassay analyzer test menu.
- **Q3 2024: Beckman Coulter Diagnostics Receives FDA Clearance for DxI 9000 Access Immunoassay Analyzer** Beckman Coulter Diagnostics announced FDA clearance for its DxI 9000 Access Immunoassay Analyzer, a high-throughput system designed to improve laboratory workflow and efficiency.
- **Q4 2024: Siemens Healthineers to acquire immunoassay technology startup for $250 million** Siemens Healthineers announced an agreement to acquire a privately held immunoassay technology startup, aiming to strengthen its diagnostics portfolio and accelerate innovation in automated immunoassay analyzers.
- **Q4 2024: Mindray Launches CL-900i Plus Chemiluminescence Immunoassay Analyzer Globally** Mindray announced the global launch of its CL-900i Plus [chemiluminescence immunoassay analyzer](https://www.marketresearchfuture.com/reports/chemiluminescence-immunoassay-analyzers-market-8783), designed for high-throughput and fully automated laboratory testing.
- **Q1 2025: Sysmex Launches HISCL-800 Immunoassay Analyzer in Japan** Sysmex Corporation launched the HISCL-800, a compact immunoassay analyzer for clinical laboratories, expanding its product offerings in the Japanese diagnostics market.
- **Q1 2025: Abbott Receives FDA Clearance for New Immunoassay Test on Alinity i Analyzer** Abbott announced FDA clearance for a new immunoassay test on its Alinity i analyzer, further expanding its menu of diagnostic tests for U.S. laboratories.
- **Q2 2025: BioMérieux Announces Partnership with Diagnostic Robotics to Integrate AI with Immunoassay Analyzers Market** BioMérieux entered a partnership with Diagnostic Robotics to integrate artificial intelligence into its immunoassay analyzer platforms, aiming to enhance diagnostic accuracy and workflow automation.
- **Q2 2025: Roche Receives CE Mark for New High-Sensitivity Troponin Immunoassay** Roche received CE Mark approval for its new high-sensitivity troponin immunoassay, designed for use on its cobas e analyzers to aid in the early diagnosis of myocardial infarction.

## Report Scope

| MARKET SIZE 2024 | 1.222(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.288(USD Billion) |
| MARKET SIZE 2035 | 2.179(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.4% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Ortho Clinical Diagnostics (US), Beckman Coulter (US), Bio-Rad Laboratories (US), PerkinElmer (US), Molecular Devices (US) |
| Segments Covered | Instruments, Application, End-User, Region |
| Key Market Opportunities | Integration of artificial intelligence enhances diagnostic accuracy in the Immunoassay Analyzers Market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the Immunoassay Analyzers Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Immunoassay Analyzers Market by 2035?**
A: The Immunoassay Analyzers Market is projected to reach a valuation of 2.179 USD Billion by 2035.

**Q: What was the market valuation of the Immunoassay Analyzers Market in 2024?**
A: In 2024, the market valuation of the Immunoassay Analyzers Market was 1.222 USD Billion.

**Q: What is the expected CAGR for the Immunoassay Analyzers Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Immunoassay Analyzers Market during the forecast period 2025 - 2035 is 5.4%.

**Q: Which segment of the Immunoassay Analyzers Market had the highest valuation in 2024?**
A: In 2024, the Chemiluminescence segment had the highest valuation at 0.488 USD Billion.

**Q: What are the key applications driving the Immunoassay Analyzers Market?**
A: Key applications driving the market include Infectious Diseases, Autoimmune Diseases, and AIDS, with valuations of 0.49, 0.4, and 0.332 USD Billion respectively in 2024.

**Q: Who are the leading players in the Immunoassay Analyzers Market?**
A: Leading players in the Immunoassay Analyzers Market include Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers.

**Q: What was the valuation of the ELISA segment in 2024?**
A: The ELISA segment was valued at 0.366 USD Billion in 2024.

**Q: Which end-user segment is expected to dominate the Immunoassay Analyzers Market?**
A: The Hospitals end-user segment is expected to dominate the market, with a valuation of 1.222 USD Billion in 2024.

**Q: What is the projected growth trend for the Immunoassay Analyzers Market?**
A: The Immunoassay Analyzers Market is likely to experience steady growth, reaching 2.179 USD Billion by 2035.

**Q: How does the Radioimmunoassay segment compare to other segments in 2024?**
A: In 2024, the Radioimmunoassay segment had a valuation of 0.124 USD Billion, which is lower compared to other segments like Chemiluminescence and ELISA.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/immunoassay-analyzers-market-1200*